RxDoctor Payments DataLook up a doctor →

Brett Bielory, MD

Ophthalmology · Rutherford, NJNPI 1437592946

Payments from drug & device makers

$477,149in general payments, 2019–2025

Across 778 payments — averaging $613.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$249K
  • Rayner Intraocular Lenses Limited$91K
  • Bausch & Lomb Americas Inc.$52K
  • Topcon Healthcare, Inc.$40K
  • Carl Zeiss Meditec, Inc.$10K
  • Amgen$9K
  • plus $25K from 29 others

What the payments were for

  • Consulting fees$234,35049%
  • Speaking & faculty fees$154,76232%
  • Travel & lodging$68,16714%
  • Food & beverage$19,8704%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$477,149 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$128,517
Medicare patients
157
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj13$613,654
MieboPerfluorohexyloctane/Pf136$183,314
RestasisCyclosporine101$91,225
XiidraLifitegrast43$65,413
Cyclosporine69$60,815
CequaCyclosporine34$30,159
TyrvayaVarenicline Tartrate14$22,621
VyzultaLatanoprostene Bunod30$18,945
LotemaxLoteprednol Etabonate28$9,789
ProlensaBromfenac Sodium26$8,459
Restasis MultidoseCyclosporine13$8,026
EysuvisLoteprednol Etabonate16$7,800
RhopressaNetarsudil Mesylate13$5,364
Prednisolone Acetate117$3,802
Bepotastine Besilate16$3,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$4,366$613,65413 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$52,001$267,672209 claims
AbbVieRestasis, Restasis Multidose$515$99,251114 claims
Sun Pharmaceutical Industries Inc.Cequa$291$30,15934 claims
Oyster Point Pharma, Inc.Tyrvaya$47$22,62114 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Prolensa$82$18,24854 claims
Kala Pharmaceuticals, Inc.Eysuvis$179$7,80016 claims
Eyevance Pharmaceuticals LLCTobradex St, Flarex$135$4,68228 claims
AlconSimbrinza$927$3,15114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Rutherford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →